Relugolix is an oral medication used to lower testosterone levels in men with advanced prostate cancer. It works differently from traditional hormone treatments by avoiding sudden testosterone spikes that can worsen the disease. It possibly also has a lower risk of heart-related side effects compared with leuprolide, a commonly used alternative.

Treating advanced prostate cancer often requires combining testosterone-lowering therapy with other medications that block cancer growth, such as enzalutamide, apalutamide, abiraterone, and darolutamide. However, concerns about how these drugs might interact have limited the wider use of relugolix.

Recent clinical studies and real-world experiences suggest that relugolix can be safely used with these additional treatments without reducing its effectiveness. These findings are promising, although more research is needed to confirm the best way to use relugolix as part of combination therapy.